Dry Granulation Overrides Direct Compression at Prednisolone Loadings Below 5 wt%

Prednisolone (Hydroprednisone) base for veterinary tablet manufacture is handled as a micronised powder with a typical D90 below 15 µm to maintain dissolution in low-dose compressible matrices. The API is pre-blended with microcrystalline cellulose at an API-to-diluent ratio between 1:10 and 1:20 for common dose strengths of 1 mg, 2.5 mg, 5 mg, and 10 mg in companion animal anti-inflammatory therapy. Crospovidone is introduced at 2–5 wt% as a disintegrant, and magnesium stearate is added last at 0.25–0.75 wt% using a low-shear bin blender at 12–18 rpm for 5–10 min. Because the active represents less than 5 wt% of the tablet mass, in-process sampling follows USP <905>; stratified samples are collected from at least 10 points across the press run, and the acceptance value is maintained below 15. Direct compression is performed on a rotary tablet press with 9 mm round tooling and a compression force range of 8–15 kN. When direct compression yields weight coefficient of variation above 2%, dry granulation is substituted. The slugged granulate is milled through an oscillating granulator fitted with a 0.8 mm screen; granules retained between 150 µm and 850 µm are collected for compression. Tablet breaking force is maintained at 40–80 N per USP <1217>, friability is controlled below 0.8% per USP <1216>, and dissolution is tested under USP <711> Apparatus 2 at 50 rpm in 0.1 M hydrochloric acid at 37 °C; the typical acceptance criterion is Q = 80% released at 30 min. Scored tooling is used for split-dose tapering in canine therapy, and the hardness window is tightened to avoid chipping edges below 35 N.

The manufacturing line for prednisolone veterinary tablets must separate corticosteroid-containing equipment from non-steroidal products because even trace carryover can suppress immune response in treated animals. A dedicated suite with negative-pressure containment and high-efficiency particulate air filtration is commonly used. In addition, final blend moisture is held below 2.0% by loss-on-drying per USP <731>; higher moisture increases the risk of sticking to the punch faces at compression forces above 12 kN. The terminal product is film-coated with an aqueous HPMC system at 2–3 wt% weight gain to mask bitterness and protect the API from light. Tablets are packaged in amber glass or opaque PVC/PVDC-aluminium blisters for companion animal dispensing.

Terminal Sterilisation Constraints in Prednisolone Parenteral Suspensions

In parenteral manufacturing, the low aqueous solubility of prednisolone base defines two product platforms: sterile micronised suspension for intramuscular or subcutaneous administration and water-soluble sodium succinate salt for intravenous reconstitution. Terminal moist-heat sterilisation at 121 °C for 15 min is not routinely applied to the suspension because the high-temperature cycle increases particle aggregation and shifts the D50 beyond 20 µm, which obstructs 21-gauge or 23-gauge needles. Suspension manufacture is therefore conducted as an aseptic process. The API is decontaminated by dry heat or gamma irradiation, then dispersed in a vehicle containing 5% w/v PEG 3350, 0.9% w/v sodium chloride, and 0.1% w/v polysorbate 80. A high-shear rotor-stator mixer running at 8,000–12,000 rpm prepares the premix; particle size reduction is completed on a high-pressure homogeniser at 500–1,000 bar to obtain a D90 between 10 µm and 20 µm. The final suspension is filled aseptically into Type I glass vials under Grade A laminar flow. Each batch is tested for particulate matter per USP <788>, bacterial endotoxin per USP <85>, and sterility per USP <71>. The endotoxin limit is calculated from the maximum labelled dose and the animal body weight; a typical cut-off for small-volume veterinary corticosteroids is 2.5 EU/mL for multi-dose presentations, but sponsor-specific toxicology may establish lower values. The finished suspension concentration is typically 5 mg/mL, 10 mg/mL, or 20 mg/mL prednisolone base equivalent, depending on the species and label claim.

Lyophilised prednisolone sodium succinate for injection is a second parenteral platform. The sodium succinate salt dissolves readily in water for injection at 20–25 °C; after clarification through a 0.22 µm PVDF membrane, the solution is filled and lyophilised in a shelf freeze dryer with a product temperature from −40 °C to +20 °C over 48–72 h. The lyophilised cake is reconstituted with sterile water for injection to 10 mg/mL prednisolone base equivalent immediately before administration. Residual moisture in the cake is controlled below 2.0% by Karl Fischer titration per USP <921>. Terminal sterilisation of the sodium succinate solution by steam autoclave is feasible in principle, but published data for this specific configuration is limited; degradation to 17-deoxy derivatives can occur if the solution is held above 60 °C for more than 8 h. The manufacturing line therefore relies on aseptic filling after sterilising filtration. For large-animal parenteral administration, the commercial product is supplied in multi-dose vials with a preservative such as benzyl alcohol at 1.5% v/v; for small animals and equine intravenous use, single-dose unpreserved vials are used to avoid preservative-related toxicity.

Equine and small-animal capsule formulations are produced as 5 mg, 10 mg, and 25 mg hypromellose capsules. The micronised prednisolone base is pre-blended with lactose monohydrate at an API-to-diluent ratio of 1:5 to 1:25, then passed through a 500 µm sieve; croscarmellose sodium is added at 1–3 wt% as the disintegrant. Magnesium stearate is restricted to 0.25–0.5 wt% because higher concentrations extend disintegration beyond 15 min in water at 37 °C. The blend is filled on a semi-automatic dosator encapsulator or a high-speed pin-tamp machine at 600–1,200 capsules/min. Content uniformity is monitored by USP <905>, and dissolution is performed in 0.1 M hydrochloric acid under USP <711> Apparatus 2 at 50 rpm; the release target is Q = 75% at 45 min. The capsule shell hygroscopicity defines the process window: the filling suite is held at 35–50% RH and 20–25 °C. Above 60% RH, hypromellose caps become tacky and cause splitting; below 25% RH, static charge promotes API adhesion to the machine surfaces, increasing weight coefficient of variation above 2%. To contain this low-dose corticosteroid, the encapsulation line is enclosed; final blend samples are pulled at 10-minute intervals and assayed by stability-indicating HPLC per Ph. Eur. 2.2.29 or USP <621>. The filled capsules are sealed with a band or lock ring and packaged in PVC/aluminium blisters to prevent moisture ingress and photodegradation. The finished capsule is intended for short-term anti-inflammatory courses in horses and dogs; label instructions typically include a tapering schedule, and the manufacturer must not imprint the capsule with livestock withdrawal information because this format is not authorised for food-producing animals in most jurisdictions.

When a Swine Drinking Water Premix Requires pH Buffering and Light-Protected Packaging

Because the unmodified steroid has an aqueous solubility only in the range of 0.2–0.3 mg/mL at 25 °C, prednisolone base cannot be used directly in drinking water. Soluble powder and granule formulations therefore employ the sodium phosphate ester or sodium succinate salt, which dissolves at 50–200 mg/mL in water. The granulate is composed of 5–20 wt% prednisolone sodium phosphate, a citrate buffer system at 0.2–0.5 mol/L to maintain pH 6.5–7.5, dextrose or lactose monohydrate as the carrier, and colloidal silicon dioxide at 0.3–0.8 wt% to control flow. Wet granulation is carried out in a fluidised-bed top-spray granulator with inlet air at 50–60 °C, product temperature at 30–40 °C, and a 2 wt% PVP K30 binder solution sprayed at 20–40 g/min per 10 kg batch. The granules are dried to a loss-on-drying below 2.0% per USP <731> and sieved through a 850 µm screen. The final product is packed in laminated aluminium-foil pouches, because prednisolone phosphate undergoes photolytic degradation in clear containers; photostability is verified under ICH Q1B conditions. At the farm, one gram of granulate is dissolved in 100 L drinking water to deliver 10 mg/L prednisolone base equivalent for swine respiratory inflammation, although the exact use concentration is governed by the marketing authorisation and species-specific withdrawal period. The dissolution point requires active stirring for 3–5 min; water containing high levels of divalent cations above 200 ppm hardness may reduce dissolution rate and should be assessed by conductivity testing before administration.

Process conflict in this format is the stability of the phosphate ester against hydrolysis at low pH. If the drinking water source is acidified below pH 5.0 for farm hygiene programmes, the phosphate group can hydrolyse and the free base can precipitate, causing dose variability and clogging of nipple drinkers. The citrate buffer concentration is therefore adjusted based on water alkalinity determined by acid titration. A 0.5 mol/L citrate buffer may be required for hard water above 150 ppm calcium carbonate equivalents. Bulk powder blending is performed in a double-cone blender at 50–70% working volume for 20–30 min; homogeneity is tested by assay on 10 sampled points with relative standard deviation below 5%. The product is labelled for use in swine and poultry only where authorised; the manufacturer must state the withdrawal period for meat and offal, and the API release tests include residual solvents according to VICH GL18 and related-production metals per Ph. Eur. 2.4.8. The granulated oral powder is not interchangeable with tablet formulations because the sodium phosphate salt has a different bioavailability profile; this is a terminal formulation difference, not a trivial diluent replacement.

In medicated feed premix production, the corticosteroid is handled as a low-level active diluted onto ground corn cob, rice hull, or mineral carrier. A typical premix contains 1–10 g prednisolone activity per 1 kg premix; the mill then adds the premix to finished feed at 1:100 or 1:1,000 dilution to achieve a final concentration in the 1–10 ppm range where authorised by national registration. The API is first slurried in 2–5 wt% refined vegetable oil or medium-chain triglyceride to suppress dust generation, which is a critical occupational and cross-contamination hazard for corticosteroids. The oil slurry is sprayed onto the carrier inside a horizontal ribbon blender or single-rotor paddle mixer operated at 60–80% working volume. Mixing time is validated for each batch size by collecting 10 thief samples from the moving bed after 10 min, 15 min, and 20 min; a coefficient of variation below 5% is required before discharge. Carryover into non-target feed is a recognised pharmacological risk. The blender, bucket elevator, and drag conveyor are therefore cleaned with a three-step sequence of dry corn flush, hot water and detergent at 60 °C, and a final dry flush until prednisolone is not detected by HPLC at the method quantitation limit. If the premix is pelleted, the mash is conditioned with steam at 70–85 °C and passed through a pellet die with a compression ratio of 1:8 to 1:12; published data for this specific configuration is limited, but the base steroid is less susceptible to thermal degradation than its phosphate ester. The finished medicated feed is labelled with a withdrawal period where food-producing animals are authorised; the label must state species, class of animal, use rate, and the complete feeding directions. This premix format is ordinarily reserved for swine and poultry in jurisdictions that permit corticosteroid medicated feed; it is not used in ruminants unless specifically authorised, because prednisolone may depress immune response and mask infection.

Does Vehicle pH or Co-solvent Content Govern Stability of Prednisolone Oral Solution?

The design space for oral solution is bounded by ester hydrolysis and C17 side-chain oxidation. Prednisolone sodium phosphate oral solution is formulated at 5 mg/5 mL or 15 mg/5 mL base equivalent for small animals. The pH is buffered with citrate or phosphate to 6.0–7.5; at pH below 5.0 the phosphate ester hydrolyses to the poorly soluble base, and at pH above 8.0 the C17 side-chain degradation rate increases. The vehicle includes 20–30 vol% propylene glycol and 10–20 vol% non-crystallising sorbitol solution to maintain solubility. Disodium edetate is added at 0.1–0.2 wt% as a chelator for iron and copper ions that promote oxidative degradation. Sodium metabisulfite at 0.05–0.1 wt% is used only when authorised, because sulfite-containing solutions can produce hypersensitivity reactions in some species. The bulk solution is circulated through a 0.45 µm polypropylene cartridge filter and filled into amber polyethylene terephthalate bottles with child-resistant closures. Fill volume control is maintained to ±1.5% of the declared volume. The finished product is stored at 15–25 °C; refrigeration below 8 °C may cause sorbitol crystallisation or turbidity without necessarily indicating API degradation. Stability-indicating HPLC is conducted according to USP <621> or Ph. Eur. 2.2.29; prednisolone is separated from 17-keto and 21-aldehyde degradation products with relative retention times of 0.6–0.8 and 1.2–1.4, respectively. The oral solution is used for dose titration in dogs and cats; the dropper or dosing syringe is graduated to 0.1 mL increments to permit tapering of the anti-inflammatory dose.

Manufacturing control for oral solution concentrates on microbial quality because the aqueous vehicle contains carbohydrate. The solution is preserved with potassium sorbate at 0.1–0.2 wt% and sodium benzoate at 0.1 wt%, and antimicrobial effectiveness is verified by USP <51>. Total aerobic microbial count is maintained below 10² CFU/mL, and the absence of Escherichia coli is confirmed per USP <62>. The terminal filter must not be degassed because high shear can introduce bubbles that cause underweight fills. The batch record lists the density of the solution at 20 °C for gravimetric fill reconciliation; a typical density is 1.05–1.15 g/mL. If the solution is prepared from the sodium phosphate salt, the label expresses the concentration as prednisolone base equivalent to avoid dosing errors. The oral solution is not diluted with fruit juice or milk before administration because pH shift and calcium-binding can reduce chemical stability; this is an in-use stability boundary communicated to the veterinarian, not a manufacturing variable.